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ABSTRACT: We develop a CHARMM-based interaction potential for rosiglitazone, a
well-known selective ligand to the c isoform of the peroxisome proliferator-activated
receptor (PPARc) and widely marketed antidiabetic drug of the thiazolidinedione (TZD)
class. We derive partial atomic charges and dihedral torsion potentials for seven
rotations in the molecule, for which there are no analogs available in CHARMM. The
potential model is validated by performing a series of molecular dynamics simulations
of rosiglitazone in neat water and of a fully solvated rosiglitazone-PPARc complex. The
structural and dynamical behavior of the complex is analyzed in comparison with
available experimental data. The potential parameters derived here are readily
transferable to a variety of pharmaceutically important TZD compounds. VC 2010 Wiley
Periodicals, Inc. Int J Quantum Chem 111: 1346–1354, 2011
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1. Introduction
T he nuclear receptor superfamily comprises agroup of roughly 48 proteins responsible for
regulation of gene transcriptional activity by
means of hormone binding [1]. The c isoform of
the peroxisome proliferator-activated receptor
(PPARc) is a key receptor in the regulation of cell
differentiation and proliferation [2]. PPARc is also
involved in inflammatory and immune responses
and is highly expressed in various types of cancer
and associated with type II diabetes [3]. PPARc
forms heterodimers with the retinoid X receptor
(RXR), which is the necessary partner for DNA
binding and transcription. RXR, activated by its
natural ligand 9-cis retinoic acid, serves as hetero-
dimeric partner for many nuclear receptors [1].
The more promiscuous PPARc accommodates
various types of ligands, mostly agonists.
Experimental techniques to identify novel
ligands and to determine the crystal structure of
Additional Supporting Information may be found in the
online version of this article.
Correspondence to: M. S. Skaf; e-mail: skaf@iqm.unicamp.br
Contract grant sponsors: Brazilian Agencies Fapesp, CNPq.
International Journal of Quantum Chemistry, Vol 111, 1346–1354 (2011)
VC 2010 Wiley Periodicals, Inc.
receptors are quite advanced. However, the
dynamic interactions of receptor, DNA response
elements, and ligands remain poorly understood.
Computational methods, such as molecular
dynamics (MD), admit studies of association and
dissociation processes [4–10], as well as the
molecular mechanisms involved in receptor acti-
vation which give insight in ligand selectivity [11,
12]. The force fields primarily derived for molecu-
lar mechanics of macromolecules, such proteins,
saccharides, lipids, and nucleic acids, do not pro-
vide parameters for specific chemical compounds,
such as the thiazolidinediones (TZD), a well-
known group of PPARc agonists, of which rosigli-
tazone among others have been clinically studied
and produced by the pharmaceutical industry
[13].
The TZDs appear in two enantiomeric forms
(R)-(þ) and (S)-(), due to the stereogenic center
at atom C5 of the thiazolidine ring (Fig. 1). Higher
antidiabetic activity have been predicted for the
(S)-() enantiomer of rosiglitazone [14], which
also is the observed form in the available crystal-
lized PPARc structures in the Protein Data Bank
(PDB) [15]. Therefore, a complete set of parame-
ters for the two enantiomers of rosiglitazone are
derived here for future studies, especially the
interactions the (S)-() enantiomer with nuclear
receptors. The particular parameterization chosen
for these simulations is based on the CHARMM
force field for biomolecular systems [16]. The
potential energy function is expressed by Eq. (1)
as follows:
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X
bonds
Kbðr r0;bÞ2 þ
X
UB
KUBðS S0;UBÞ2
þ
X
angle
Kaðh h0;aÞ2 þ
X
dihedrals
Kd;n 1þ cos nv dd;n
  
þ
X
impropers
Ki w w0;i
 2
þ
X
nonbonded
eij
Rmin;ij
rij
 12
2 Rmin;ij
rij
 6" #
þ qiqj
4pe0rij
;
ð1Þ
where the sums extend to all bond stretchings,
Urey-Bradley terms, angle bendings, dihedral tor-
sions, improper dihedrals, and nonbonded van
der Waals and Coulombic interactions. There are
potential parameters developed for a great variety
of biomolecules [17–20]. The transferability of pa-
rameters between molecules is the basic principle
of these force fields, so parameters from similar
molecules should be used whenever possible.
However, for markedly flexible molecules, the
sampling over different conformational states
dependent critically on torsion (dihedral angle)
potentials, so obtaining accurate torsional parame-
ters derived from quantum mechanical potential
energy surface (PES) scans of a given particular
molecule is highly desirable [21].
In this work, we propose a complete set of
CHARMM compatible force field parameters for
rosiglitazone. Our main goal is to generate a force
field for this molecule which is suitable for
further computer simulation studies of the
FIGURE 1. Chemical structure of rosiglitazone. The arc-shaped arrows indicate the torsion (T) of the eight bonds for
which full revolution is possible.
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interactions between the drug and its known tar-
get receptor and other proteins. Partial point
charges are computed, CHARMM force field
atom types assigned, and similar bond lengths,
bond angles, Urey-Bradley, dihedral, and
improper dihedral parameters for atom combina-
tions not included in CHARMM are adopted.
Finally, novel torsional parameters for seven dihe-
dral rotations are derived based on CHARMM
procedures. The newly parameterized model for
rosiglitazone is tested by performing molecular
dynamics (MD) simulations of this molecule in
aqueous solutions and bound to the ligand bind-
ing domain (LBD) of PPARc. We examine the
simulated structure and dynamics of the rosiglta-
zone-LBD complex in comparison with available
experimental data and find that the proposed
model is very-well behaved as far as these prop-
erties are concerned.
Because all TZDs share the same molecular
backbone, the torsion potentials derived here are
readily transferred to a series of pharmaceutically
important compounds used in the treatment of
type II diabetes, such as pioglitazone, troglitazone,
rivoglitazone, and ciglitazone, to name few. There
are two specific features in the molecular structure
of the TZDs for which adequate CHARMM param-
eters were so far unavailable. One of them is the
five-member heterocyclic aromatic ring containing
S1 and N3 atoms for which there are neither
CHARMM partial charges nor parameters for the
T1 torsion (Fig. 1). On the other end of the mole-
cule, there is an unusual pyridine ring containing a
sp2 nitrogen (N18), also not available in
CHARMM, which greatly affects the potential bar-
rier for the T7 torsion (Fig. 1).
2. Parameterization and
Computational Details
The force field parameters are developed at the
restricted Hartree-Fock (RHF) ab initio level of
theory with the 6-31G(d) basis set in consistency
with the CHARMM parameterization of the c35b2
release. All ab initio calculations are performed
with the Gaussian03 package revision E.01 [22],
whereas classical force field potential energies are
computed with the NAMD package [23], which is
also used for the evaluative MD simulations. The
acid dissociation constant (pKa) of rosiglitazone is
estimated with ALOGPS [24, 25].
For the self-consistent field (SCF) procedure,
the default combination of the EDIIS and the
CDIIS algorithms, with no damping or Fermi
broadening, is used. The convergence criteria (in
atomic units) are 1.0  106 for the energy, 1.0 
106 for the maximum of density matrix, and
1.0  108 for the root mean square (RMS) of den-
sity matrix. The geometry is relaxed with the
implemented version of the Berny geometry opti-
mization algorithm and the convergence criteria
(in atomic units) are 1.5  105 for maximum
force, 1.0  105 for RMS force, 6.0  105 for
maximum displacement, and 4.0  105 for RMS
displacement. All four criteria were simultane-
ously satisfied.
Stationary points for RHF/6-31G(d) as well as
with the more accurate 6-311G(d,p) basis set
using both RHF and density functional theory
DFT/B3LYP methods are obtained to evaluate the
minimum of the first method. The partial point
charge calculation is, however, based on the
RHF/6-31G(d) geometry for consistency with
CHARMM. Net atomic charges are derived to fit
the RHF/6-31G(d) electrostatic potential of the
relaxed structure. The sampling points are
selected according to the employed Merz-Singh-
Kollman approach [26, 27] in 10 layers and
17 grid point per unit area resulting in 95,155
points (the default is four layers and one point
per unit area, giving 1,850 points for rosiglita-
zone.) The charges are also constrained to repro-
duce the molecular dipole moment. The atoms
are classified in atom types of the CHARMM22
all-atom force field for proteins [17, 18] (release
c35b2), based on the derived charges and the local
chemical environment. Unavailable parameters
are adopted primarily from similar groups of the
all-atom force field for proteins CHARMM22
(release c35b2) and to less extent from
CHARMM27 for nucleic acids [19, 20] and
CHARMM32 for esters [28, 29] (of the same
release).
The flexibility of the ligand is an important fac-
tor for their binding modes in the active site of
the LBD and influence the ligand dissociation
mechanism [4–7, 10]. The structure of rosiglita-
zone admits full revolution around eight bonds,
as depicted in Fig. 1. The dihedral angle parame-
ters required for describing the torsional barriers
are not included in the current releases of
CHARMM. Therefore, all torsional rotations,
excluding the rotation of the CH3 group, are para-
meterized. To avoid interference with the existing
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dihedral parameters and to obtain unique set of
dihedral angle parameters for the seven rotating
bonds, a few atom type aliases are introduced.
To calculate the rotational energy profiles, the
quadruples C4-C5-C6-C7, C5-C6-C7-C8, C9-C10-
O13-C14, C10-O13-C14-C15, O13-C14-C15-N16,
C14-C15-N16-C17, and C15-N16-C17-N18 define
the dihedral torsions T1–T7, respectively. The
energy profiles are obtained from rotational scans
at 20 degree steps with a RHF/6-31G(d) geometry
relaxation where only the regarded rotational
angle is fixed. These energy profiles correspond
to the total quantum mechanical potential energy,
which in some cases differ substantially from the
dihedral torsion potential energy, despite the
relaxed geometry, mainly due to the constant
point charge model. The missing classical dihe-
dral torsion potential as follows:
VdðvÞ ¼
X
n¼1
Kd;nð1þ cosðnv dd;nÞÞ; (2)
is obtained for each dihedral torsion by least-
square fitting this expression to the difference
between the quantum and the molecular mechan-
ics energy profiles. Since dihedral angle parame-
ters are unknown for seven rotational barriers, the
fitting procedure was conveniently done repeat-
edly, in a self-consistent manner, until conver-
gence of all torsion potentials. The potential
energy of the molecular mechanics force field is
calculated with the NAMD2.7 package [23] via
the NAMDENERGY plug-in of VMD [30]. Only
terms with multiplicity n  6 are considered and,
as far as possible, phase angles d are multiples of
180, consistent with CHARMM. The obtained
parameters for the dihedral angles defined by the
aforementioned quadruples describe solely the
total dihedral angle potential for each bond rota-
tion. Hence, the other force constants of the
involved dihedral angles are kept as zero.
Finally, MD simulations are performed to eval-
uate the developed parameters. Both rosiglitazone
solvated in a box containing 1,828 water mole-
cules at ambient conditions and rosiglitazone
bound to the LBD of PPARc (fully hydrated) are
studied. The structure of the ligand–receptor
complex, based on the ligand binding domain
of the PDB structure 1FM6, chain D [31], is fully
solvated by 18,000 water molecules, 28 Naþ
and 23 Cl ions, reaching a concentration of
0.15 mol/L to obtain a neutral system. Struc-
tural (crystallographic) water molecules within a
distance of 4 A˚ from the protein are retained. The
hydration shell around the protein is at least 15 A˚
thick and the entire system is enclosed in ortho-
rhombic box with periodic boundary conditions.
Langevin dynamics is employed to simulate the
isothermal-isobaric ensemble at 300 K and 1.0
atm. The velocity Verlet algorithm is used for
time integration with a time step of 2.0 fs. Full
Coulomb forces are computed with the particle
mesh Ewald algorithm [32], whereas van der
Waals forces are truncated with a 12 A˚ smooth
switching cutoff. The systems are initially relaxed
with the default conjugate gradient and line
search algorithm (CG) of NAMD2.7. We used the
TIP3P model [33] for water and CHARMM
parameters for the protein and counterions.
The following protocols are used for equilibrat-
ing the two systems. Rosiglitazone in water: (1)
300 steps of CG, keeping all atoms of rosiglita-
zone fixed; (2) 600 steps of CG, without any
restraint; (3) 1,000 ps of MD without any restraint.
The ligand–receptor complex in solvent: (1) 2,000
steps of CG, with all atoms of the protein fixed;
(2) 200 ps of MD with all atoms of the protein
fixed; (3) 500 steps of CG, with the Ca atoms
fixed; (4) 200 ps of MD with the Ca fixed; (5) 400
ps of MD without any restraint. Finally, 6 ns MD
simulations were performed starting from the
equilibrated structures. The trajectories of first
1 ns of these simulations were discarded. This
protocol was repeated 20 times for the ligand–
receptor complex; thus, 20 independent 5 ns MD
simulations were obtained for data analysis.
3. Results and Discussion
First the neutral state of (S)-()-rosiglitazone in
neat water is considered. The structure is relaxed
(in atomic units) to a maximum force of 1.0 
106, RMS force of 1.0  107, maximum dis-
placement of 1.9  105, and RMS displacement
of 0.3  105. This geometry has total energy of
1478.1721 atomic units, which has converged to
0.37  108, and its dipole moment is 3.014 D. On
the basis of this configuration, we estimated the
acid dissociation constants for rosiglitazone to
6.9 (base part) and 6.5 (acid part), as described
above. The values are consistent with the litera-
ture [34]. At physiological pH around 7.4 [35], the
unprotonated, neutral form of rosiglitazone (sin-
glet state) predominates. Therefore, parameters
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are derived for neutral rosiglitazone. Table I lists
the calculated Merz-Singh-Kollman partial atomic
charges for the ground state geometry. Despite
the differentiated hydrogen charges of the CH3
groups, the average 0.09 is adopted for all methyl
hydrogens, yielding 0.16 for the methyl carbons.
The ground state geometry at RHF and B3LYP
level using the 6-311G(d,p) basis set confirm
above calculated molecular conformation.
The atoms are classified in atom types of the
CHARMM22 all-atom force field for proteins
(release c35b2) based on the derived charges and
the local chemical environment (Table I). Bond,
angle, and dihedral parameters (excluding T1–T7
dihedral angles discussed below), as well as
Urey-Bradley distances and Lennard-Jones energy
and distance parameters, which could be obtained
by group analogy from the CHARMM force field,
are provided as Supporting Information.
The calculated dihedral angle PES for the tor-
sions T1–T7 and the corresponding fitting func-
tions [Eq. (2)] are depicted in Fig. 2. The top panel
(T3) also shows the ab initio quantum mechanical
PES (black dots), the molecular mechanics PES
excluding the dihedral potential for the T3 torsion
(crosses), the quantum and classical PES differ-
ence (plus signs) and the adjusted dihedral poten-
tial (solid line). For comparison, the full molecular
mechanics PES, now including the parameterized
torsional potential, is shown by empty circles. The
agreement between the quantum and the full clas-
sical force filed PESs is excellent. In the remainder
panels, only the quantum and classical PESs dif-
ferences (plus signs) and the adjusted potentials
(lines) are shown. As mentioned in ‘‘Parameter-
ization and Computational Details,’’ we have
applied the CHARMM restriction of using the
first six terms in the fitting function [cf., Eq. (2)],
which limits quality of the fit. Moreover, the
adjustments of the torsion parameters have been
carried out in a self-consistent way due to the
mutual dependence between the distinct rota-
tions. The complete set of fitted parameters thus
obtained is listed in Table II.
The first test for the force field is performed
by examining the behavior of rosiglitazone in an
TABLE I
Atom names, CHARMM atom types, and partial atomic charges derived in this work.
Atom name CHARMM typea Charge (a.u.) Atom name CHARMM typea Charge (a.u.)
S1 S 0.21 C23 CT3 0.17b
C2 C 0.60 O24 O 0.48
N3 NH1 0.62 O25 O 0.55
C4 C 0.65 H26 H 0.40
C5 CT2 0.08 H27 HA 0.06
C6 CT2 0.04 H28 HA 0.05
C7 CA 0.13 H29 HA 0.06
C8 CA 0.01 H30 HP 0.12
C9 CA 0.44 H31 HP 0.19
C10 CA 0.48 H32 HP 0.16
C11 CA 0.37 H33 HP 0.11
C12 CA 0.01 H34 HA 0.01
O13 OH1 0.38 H35 HA 0.06
C14 CT2 0.21 H36 HA 0.12
C15 CT2 0.14 H37 HA 0.08
N16 NC2 0.35 H38 HA 0.12c
C17 C 0.91 H39 HA 0.09c
N18 NC2 0.71 H40 HA 0.07c
C19 C 0.36 H41 HP 0.07
C20 CA 0.55 H42 HP 0.20
C21 CA 0.23 H43 HP 0.11
C22 CA 0.69 H44 HP 0.23
aCHARMM22 all-atom force field for proteins.
b0.16 is used for the force field.
c 0.09 is used for the force field.
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aqueous environment. The average geometry of
the molecule in water closely replicates the ab
initio relaxed geometry after the initial relaxation
of the system. Structural aligning of the geome-
tries, where all atoms are taken into account,
gives a root mean square deviation (RMSD) of
only 0.18 A˚. The planarity of the three rings is
maintained during the simulation, so no addi-
tional improper dihedral angles are therefore
included.
FIGURE 2. Torsion energies of the bonds C5-C6 (T1), C6-C7 (T2), C10-O13 (T3), O13-C14 (T4), C14-C15 (T5), C15-
N16 (T6), and N16-C17 (T7). The black dots represent the ab initio PES, whereas the crosses (x) indicate the force
field PES without the considered dihedral angle. The difference between them is shown by plus signs (þ) and the
adjusted potential energy of the dihedral angle is depicted by a solid line. For comparison, the circles show the total
force field, including the parameterized dihedral angle.
CHARMM FORCE FIELD PARAMETERIZATION OF ROSIGLITAZONE
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The main evaluation comes from examining
the behavior of the ligand and its target nuclear
receptor protein PPARc in the ligand–receptor
complex. In all currently reported structures in
PDB containing rosiglitazone (PDB IDs: 1FM6,
1ZGY, 2PRG, 3CS8, and 3DZY), it appears
bounded to the LBD pocket of PPARc. One of the
highest resolution structures of the ligand-LBD
complex is the 1FM6 structure, with a resolution
of 2.10 A˚. Therefore, our evaluative simulations of
rosiglitazone interacting with the PPARc LBD
start from the 1FM6 structure.
The average structure of the rosiglitazone-LBD
complex over 20 independent 5 ns simulations
yields a RMSD of only 0.99 A˚ after a structural
alignment with the initial crystal structure
[Fig. 3(a)]. The RMSD between the average simu-
lated and crystal structures of rosiglitazone itself is
only 0.35 A˚. The average structure of rosiglitazone
obtained from each 5 ns simulation and the crystal
structure are visualized in Fig. 3(b), after alignment
of the LBDs, indicating that the PPARc LBD
remains very stable and structurally well-correlated
with the crystallographic structure in the presence
of the parameterized ligand. In addition, the aver-
age conformation and position of rosiglitazone
inside the ligand binding pocket (i.e., the ligand
binding mode), preserve the crystal conformation
and the crystalline ligand-LBD contacts. These
results indicate that the ligand–protein and ligand
intramolecular interactions are well accounted for
by the proposed interaction potential.
The available experimental data of rosiglita-
zone regarding its dynamical behavior is limited
to the crystallographic Debye-Waller or tempera-
ture B-factors. A comparison between the crystal-
lographic and simulated B-factors is presented in
Fig. 4, showing very good agreement, apart from
an overall multiplicative factor, which is common
in this type of comparison because the crystallo-
graphic B-factors depend on the structure resolu-
tion. The mobility of the different structural
elements of the LBD derived from diffraction data
are well-reproduced by the motions of rosiglita-
zone obtained from the MD simulations with the
proposed model.
TABLE II
Dihedral parameters for seven torsional rotations.
Dihedral angle Kd,n (kcal/mol) N d ()
T1: C4 C5 C6 C7 0.5659 1 0.0
0.0987 2 0.0
1.0226 3 0.0
T2: C5 C6 C7 C8 0.0000 1 0.0
T3: C9 C10 O13 C14 3.7459 2 180.0
0.3416 4 180.0
T4: C10 O13 C14 C15 0.4826 1 60.0
0.9938 2 180.0
0.3873 3 90.0
T5: O13 C14 C15 N16 2.1289 1 180.0
1.1948 2 0.0
0.8041 3 0.0
0.3619 4 180.0
T6: C14 C15 N16 C17 0.2725 1 60.0
1.3384 2 45.0
T7: C15 N16 C17 N18 4.2932 2 180.0
FIGURE 3. (a) Average structure of the PPARc-
rosiglitazone complex from simulations (light gray)
superimposed to the crystallographic structure (dark
gray). (b) Average structures of rosiglitazone for
individual 5 ns simulations (light gray) and the crystal
structure (black), with the LBDs structurally aligned.
FIGURE 4. Temperature B-factors obtained from
the present simulations (A) and available from
crystallography experiments (PDB ID: 1FM6) (B).
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4. Conclusions
A CHARMM-based model has been derived
for molecular simulations of rosiglitazone, an im-
portant nuclear receptor ligand, with relevant
pharmaceutical applications in the treatment of
type II diabetes. The proposed force field enables
MD studies of the interactions of rosiglitazone
and other TZD compounds with the nuclear re-
ceptor PPARc, as well as with other proteins and
other biomolecular systems under CHARMM. We
have specially focused on the energy profiles of
the rotating bonds, which give the molecule its
characteristic flexibility and are very significant
factors for ligand association/dissociation mecha-
nisms and other features that depend on ligand
conformational adaptations. MD simulations are
being carried out for the rosiglitazone-PPARc
complex using this potential aiming to investigate
the concerted motions of different structural ele-
ments of the LBD intermediated by rosiglitazone
in the binding pocket and the pathways of ligand
dissociation from the PPARc LBD core.
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